Metabolism of the antipsychotic drug tiospirone in humans

RF Mayol, HK Jajoo, LJ Klunk and IA Blair

Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492.

Metabolism of the antipsychotic drug tiospirone was studied in humans after a single 60-mg oral dose of [14C]tiospirone. Metabolites were isolated from a 0-24 hr pooled urine from eight subjects, which represented 39% of the dose, and purified to homogeneity by HPLC. Purified metabolites were identified by desorption chemical ionization mass spectrometry in the positive ion mode with methane as a reagent gas. Structures of the metabolites were confirmed by coelution on HPLC in several systems with synthetic standards. In addition to unchanged tiospirone, five metabolites of tiospirone were identified and one additional metabolite was partially identified. Based on the structures of these metabolites, five routes of metabolism of tiospirone were identified: N-dealkylation of the butyl side chain attached to the piperazinyl nitrogen, hydroxylation alpha to the glutarimidyl carbonyl at the 6'-position on the spiro ring, hydroxylation at the 3'-position on the spiro ring, oxidation at sulfur resulting in the formation of sulfones, and oxidation at carbon alpha to the piperazinyl nitrogen resulting in the formation of a lactam-sulfone. The major urinary metabolites were benzisothiazole piperazine sulfone and its lactam derivative, accounting for 5.0 and 4.3% of the dose, respectively. The identified metabolites accounted for 50% of the total radioactivity in the urine (approximately 20% of the dose). The remaining radioactive components were extremely heterogeneous and could not be isolated in sufficient quantities to characterize. A scheme for the metabolism of tiospirone in humans is proposed.

Volume 19, Issue 2, pp. 394-399, 03/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C. Prakash, A. Kamel, J. Gummerus, and K. Wilner Metabolism and Excretion of a New Antipsychotic Drug, Ziprasidone, in Humans Drug Metab. Dispos., July 1, 1997; 25(7): 863 - 0. [Abstract] [Full Text]

				C. Prakash, A. Kamel, and D. Cui Characterization of the Novel Benzisothiazole Ring-Cleaved Products of the Antipsychotic Drug Ziprasidone Drug Metab. Dispos., July 1, 1997; 25(7): 897 - 901. [Abstract] [Full Text]

				C. Prakash, A. Kamel, W. Anderson, and H. Howard Metabolism and Excretion of the Novel Antipsychotic Drug Ziprasidone in Rats after Oral Administration of a Mixture of 14C- and 3H-Labeled Ziprasidone Drug Metab. Dispos., February 1, 1997; 25(2): 206 - 218. [Abstract] [Full Text]